Telomir Pharmaceuticals Demonstrates Promising Vision Restoration in Preclinical AMD Study
TL;DR
Telomir Pharmaceuticals (NASDAQ: TELO) announced positive preclinical results for Telomir-1, showing potential to restore vision and reverse retinal degeneration in age-related macular degeneration.
Telomir-1, a small molecule by Telomir Pharmaceuticals, improved central vision response, restored retinal architecture, reduced oxidative stress, and eliminated mortality in zebrafish AMD model.
Telomir-1's regenerative treatment for AMD offers hope for restoring visual function, structural regeneration, and promoting longevity for those affected by age-related macular degeneration.
Telomir-1's success in reversing retinal degeneration in zebrafish presents an exciting breakthrough in treating AMD and potentially enhancing quality of life for many.
Found this article helpful?
Share it with your network and spread the knowledge!
Telomir Pharmaceuticals reported significant progress in addressing age-related macular degeneration (AMD) through its experimental oral therapeutic, Telomir-1. In a 14-day preclinical study using a genetically modified zebrafish model, the drug demonstrated remarkable potential for vision restoration and retinal regeneration.
The study revealed multiple promising outcomes, including improved central vision response, comprehensive retinal architecture restoration, and a substantial 50% reduction in oxidative stress. Notably, the treatment eliminated mortality observed in untreated animals and facilitated complete visual function recovery.
Researchers observed structural regeneration across critical retinal layers, specifically in the inner nuclear and ganglion cell layers. These findings suggest Telomir-1 could represent a groundbreaking approach to treating degenerative eye conditions associated with aging.
The research aligns with Telomir's broader scientific mission of developing interventions that target fundamental aging processes. By focusing on telomere preservation—the protective DNA chromosome caps that naturally shorten with age—the company aims to develop treatments that could potentially mitigate age-related diseases.
While preclinical results are promising, further research and human trials will be necessary to validate the therapeutic potential of Telomir-1 for vision restoration and potential broader applications in longevity science.
Curated from InvestorBrandNetwork (IBN)
